<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190720044283N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-09-01</date_registration>
      <primary_sponsor>University of Guilan</primary_sponsor>
      <public_title>Acute effect of beta-alanine supplementation on anaerobic function and muscle fatigue in female athletes</public_title>
      <acronym></acronym>
      <scientific_title>Effects of Acute β-Alanine supplementation on anaerobic performance and muscle fatigue in athletic female</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>10</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58031</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Crossover, Purpose: Other, Randomization description: Using the random selection method by Excel software by writing the names of the subjects in cells and then in the other part, we specify the position of the desired groups in two separate sections of 5 subjects. Then in these two sections, we will execute the following code so that they are randomly placed in groups of 5 subjects.
=INDEX($A$3:$A$12,RANDBETWEEN(1,ROWS($A$3:$A$12)),1), Blinding description: In this study, one group will take 6 grams of beta-alanine supplement in capsules and the other group will take a placebo containing sucrose. It should be noted that capsules containing supplements or placebos will be coded by a third party who has no conflict of interest in the present study and is present merely as an observer and will distribute it with the knowledge of each individual supplement.</study_design>
      <phase>1-2</phase>
      <hc_freetext>Prevent depletion of energy resources during physical activity, Reduce or delay muscle fatigue and improve performance, Increase anaerobic power.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Beta-alanine supplementation; The intervention group took 4.5 g of beta-alanine in capsules and the other group took a placebo containing the same amount of sucrose as beta-alanine. One week after the effects of the supplement disappear, in the third session, the two groups of subjects will change in terms of supplementation, and the group that uses the beta-alanine will use a placebo. Intervention 2: Control group: The placebo group consumes 4.5 grams of sucrose in capsules. After one week, in the third session, the two groups of subjects will change in terms of supplementation, and the group that uses the placebo will use beta-alanine.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Javad Mehrabani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>8 km of Tehran road, Faculty of Physical Education and Sports Sciences, University of Guilan</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4199843653</zip>
        <telephone>+98 911 230 9074</telephone>
        <email>mehrabanij@guilan.ac.ir</email>
        <affiliation>Faculty of Physical Education and Sports Sciences, University of Guilan</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Javad Mehrabani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>8 km of Tehran road, Faculty of Physical Education and Sports Sciences, University of Guilan</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4199843653</zip>
        <telephone>+98 911 230 9074</telephone>
        <email>mehrabanij@guilan.ac.ir</email>
        <affiliation>Faculty of Physical Education and Sports Sciences, University of Guilan</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Trained girls have had at least 3 regular workout sessions a week in the past year
No musculoskeletal injuries and physical problems</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>30 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Existence of musculoskeletal injury and taking medication or supplements
Physician not confirming physical health
Alcohol or tobacco consumption</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Beta-alanine supplementation; The intervention group took 4.5 g of beta-alanine in capsules and the other group took a placebo containing the same amount of sucrose as beta-alanine. One week after the effects of the supplement disappear, in the third session, the two groups of subjects will change in terms of supplementation, and the group that uses the beta-alanine will use a placebo.</i_keyword>
      <i_keyword>Control group: The placebo group consumes 4.5 grams of sucrose in capsules. After one week, in the third session, the two groups of subjects will change in terms of supplementation, and the group that uses the placebo will use beta-alanine.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Electromyographic (EMG) indices of the quadriceps muscle. Timepoint: Implement the protocol in two steps with a one week wash-out interval and before and after supplementation. Method of measurement: Electromyography device (Muscle Tester ME 3000P8 Mega Electronic Ltd, Finland) with sampling frequency HZ 2000 and bandwidth Hz / 3 Db 450-30.</prim_outcome>
      <prim_outcome>Maximal Voluntary Contraction (MVC). Timepoint: Before and after supplementation. Method of measurement: Manual Muscle Testing Device (MMT, North coast, USA).</prim_outcome>
      <prim_outcome>Rate of Perceived Exertion (RPE). Timepoint: Immediately after the fatigue protocol (consecutive side jump). Method of measurement: Borg scale (6-20).</prim_outcome>
      <prim_outcome>Muscle Pain. Timepoint: Immediately, 24 and 48 hours after the fatigue protocol. Method of measurement: Visual Analogue Scale (VAS).</prim_outcome>
      <prim_outcome>Muscle Power. Timepoint: Before and after supplementation and Immediately after the fatigue protocol. Method of measurement: Johnson's and Bahamonde Method.</prim_outcome>
      <prim_outcome>Sense of Fatigue. Timepoint: Immediately, 24 and 48 hours after the fatigue protocol. Method of measurement: Sense of Fatigue Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of Guilan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-07-20</approval_date>
        <contact_name>Research Ethics Committee of Sports Science Institute (SSRI)</contact_name>
        <contact_address>Fifth Alley, Mir Emad St., Ostad Motahhari St. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
